Clinical Trial Update: MB-CART20.1 Melanoma [EARLY_Phase 1]

View source ↗

Summary

Miltenyi Biomedicine's MB-CART20.1 trial for melanoma (early-phase 1) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MB-CART20.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Melanoma (Skin) | EARLY_Phase 1 | Status: TERMINATED